北京大学人民医院
Peking University People's Hospital
在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
北京大学人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma2 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma24 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer21 篇牵头论文牵头 3 项开放试验
- 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
- 脊索瘤Chordoma6 篇牵头论文
- 骨肉瘤Osteosarcoma42 篇牵头论文牵头 2 项开放试验
- 胃肠道间质瘤Gastrointestinal stromal tumour8 篇牵头论文牵头 2 项开放试验
- 尤文肉瘤Ewing sarcoma7 篇牵头论文牵头 2 项开放试验
- 多发性骨髓瘤Multiple myeloma19 篇牵头论文牵头 5 项开放试验
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia19 篇牵头论文牵头 4 项开放试验
- 再生障碍性贫血Aplastic anaemia29 篇牵头论文牵头 3 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis7 篇牵头论文牵头 1 项开放试验
- 血友病 AHaemophilia A0 篇牵头论文牵头 1 项开放试验
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura4 篇牵头论文牵头 2 项开放试验
- 范可尼贫血Fanconi anaemia2 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder0 篇牵头论文牵头 1 项开放试验
- IgG4相关性疾病IgG4-related disease12 篇牵头论文牵头 1 项开放试验
- 重症肌无力Myasthenia gravis3 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
- 白塞病Behçet disease5 篇牵头论文牵头 1 项开放试验
- IgA 肾病IgA nephropathy0 篇牵头论文
- 戈谢病Gaucher disease0 篇牵头论文
- 成骨不全症Osteogenesis imperfecta2 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis7 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
- 先天性膈疝Congenital diaphragmatic hernia0 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:鼻咽癌、肝母细胞瘤、神经母细胞瘤、β 地中海贫血、非典型溶血性尿毒症综合征、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、尼曼-匹克病 C 型、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.07%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文2
PubMed 以外找到的论文(未计入)8
- Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.2%。
北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- 分期
- 不分期
- 开始
- 2025-06
- 登记号
- NCT07010588
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文24
- Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.
- Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma.
- Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.
- Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.
- Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.
- AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma.
- Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.
- Clinical potential of serum prostaglandin A2 as a novel diagnostic biomarker for hepatocellular cancer.
- All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines.
- Methodological challenges in studying immune-suppressive neutrophils in HCC models.
- For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
- Augmentation of hepatocellular carcinoma malignancy by annexin A5 through modulation of invasion and angiogenesis.
- NDRG1 facilitates self-renewal of liver cancer stem cells by preventing EpCAM ubiquitination.
- A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection.
- The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
- Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
- Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
- Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma.
- Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.
- The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.
- Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease.
- Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer.
- Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma.
- Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。
北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07857668
年龄 20 岁 至 80 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- 分期
- 不分期
- 开始
- 2024-01
- 登记号
- NCT06748690
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 即将招募Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- 分期
- II期
- 开始
- 2025-10
- 登记号
- NCT07018063
年龄 16 岁 至 45 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- 分期
- 不分期
- 开始
- 2026-07
- 登记号
- NCT07714980
年龄 18 岁 至 80 岁(登记的条件)
牵头:青岛大学附属医院;另有 5 家列出的医院为研究中心Weihai、北京、潍坊、烟台、青岛
- 正在招募AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- 分期
- 未注明
- 开始
- 2023-09
- 登记号
- NCT06035250
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文21
- Endoscopic semi-blunt dissection technique is safe and effective for treating gastric submucosal tumors from the muscularis propria.
- Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy.
- CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.
- CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors.
- Extramural venous invasion in gastric cancer: 9.4T magnetic resonance imaging assessment and circular RNA functional analysis.
- Sintilimab and Cardiovascular Toxicity.
- Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.
- Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer.
- Safety and efficacy of vagus nerve-preserving distal gastrectomy for early gastric cancer: A systematic review and meta-analysis.
- Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.
- Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
- Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer.
- Pathological diagnosis, differential diagnosis and origin investigation of easily misdiagnosed adult gastric duplication cysts.
- Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review.
- Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1.
- Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.
- Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer.
- A signature of 24 aging‑related gene pairs predict overall survival in gastric cancer.
- CT-detected extramural venous invasion-related gene signature for the overall survival prediction in patients with gastric cancer.
- Diagnosis of gastric lesions through a deep convolutional neural network.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
中文论文(未计入)5
- [Research progress on peritoneal metastasis of gastric cancer in the era of immunotherapy].
- [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].
- [Updates on the molecular classification of gastric cancer].
- [Research progress of single-incision laparoscopic radical gastrectomy].
- [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Effects of HIPEC on Postoperative Bowel Motility and Complications
- Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
这些数字背后的记录
早期论文(2016–2020 年)3
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 5.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.
- Multi-omics analysis unveils the role of inflammatory cancer-associated fibroblasts in chordoma progression.
- Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects.
- Letter to the Editor Regarding "Hypoxia-inducible Factor-1α (HIF-1α) as a Factor to Predict Prognosis of Spinal Chordoma" by He and Liu.
- The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
- Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.
中文论文(未计入)1
早期论文(2016–2020 年)6
- Epidemiological characteristics of 1385 primary sacral tumors in one institution in China.
- Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.
- A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.
- Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging.
- miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.
- One-step reconstruction with a 3D-printed, custom-made prosthesis after total en bloc sacrectomy: a technical note.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 42 篇,占 1.9%。
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- 分期
- I/II期
- 开始
- 2026-03
- 登记号
- NCT07479732
年龄 12 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- 分期
- II期
- 开始
- 2024-11
- 登记号
- NCT06714383
年龄 14 岁 至 70 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- 分期
- II期
- 开始
- 2023-06
- 登记号
- NCT05830123
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文42
- Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.
- T2-weighted magnetic resonance imaging radiogenomic features for the prediction of neoadjuvant chemotherapy response in patients with osteosarcoma.
- Sonographic characteristics of local soft tissue recurrence in primary bone tumor and diagnostic efficacy versus MRI.
- Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.
- Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation.
- End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.
- Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets.
- Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.
- CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.
- Magnetic resonance imaging assessment of epiphyseal invasion in paediatric osteosarcoma.
- Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging.
- Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma.
- Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
- Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.
- The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.
- Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
- Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.
- Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma.
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
- Intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging for neoadjuvant chemotherapy response evaluation in patients with osteosarcoma.
- Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
- Outcomes of Semiknee Replacement in Skeletally Immature Bone Sarcoma Patients.
- Outcomes of Fixed-Hinged Knee Prosthesis for Distal Femoral Osteosarcoma in Skeletally Immature Patients: First Results.
- An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
- Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
- PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
- circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p.
- Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis.
- Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.
- How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?
- Analysis of mechanical complications for patients with extremity sarcoma after biological reconstruction.
- Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.
- Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment.
- The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.
- Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China.
- Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
- The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
- RNA-dependent protein kinase is required for interferon-γ-induced autophagy in MG63 osteosarcoma cells.
- Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
- Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases.
- Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
中文论文(未计入)2
早期论文(2016–2020 年)31
- Multiple primary tumors: a case report and review of the literature.
- Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.
- Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B.
- Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.
- Lateral malleolus en bloc resection for the distal fibula osteosarcoma based on a new classification and proposed reconstruction choice: Analysis of 6 cases prognosis and literature review.
- The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
- Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
- Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.
- Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.
- Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
- Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
- Novel "double-strut" fibula ankle arthrodesis for large tumor-related bone defect of distal tibia.
- [Rasfonin inhibits proliferation and migration of osteosarcoma 143B cells].
- Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis.
- Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
- [Effectiveness of free vascularized fibular graft for bone defect after resection of lower limb malignant tumor].
- Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
- Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases.
- Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
- Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.
- Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.
- PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
- Rectus femoris branch: An alternative blood supply for a distally based anterolateral thigh flap.
- Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.
- Surgical treatment of primary malignant tumours of the distal tibia: clinical outcome and reconstructive strategies.
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.
- Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
- Surgical Treatment of Primary Osteosarcoma of the Sacrum: A Case Series of 26 Patients.
- Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
- B7-H3 NIR Imaging for Osteosarcoma Surgery
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
- Soluble B7-H3 as a Biomarker for Osteosarcoma
- Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
- Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
- Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
- Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
- Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
- Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
- Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS
- Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab
- Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
- Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
- PD-L1 Expression in Advanced Osteosarcoma
- Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
- Epigenetic Biomarker for Osteosarcoma
- Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.5%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- 分期
- 不分期
- 开始
- 2024-01
- 登记号
- NCT06748690
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- 分期
- 未注明
- 开始
- 2022-01
- 登记号
- NCT05408897
年龄未注明(登记的条件)
牵头:北京大学人民医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- Disparities in management guidelines for gastrointestinal stromal tumors: A comparison of recommendations from the Chinese Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society for Medical Oncology.
- Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition).
- CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.
- Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.
- Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis.
- Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.
- Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
中文论文(未计入)2
早期论文(2016–2020 年)6
- Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: A systematic review and meta-analysis.
- Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map.
- [Evidence-based standardized diagnosis and treatment of small gastrointestinal stromal tumors].
- [Minimally invasive surgery for gastrointestinal stromal tumors--pursuing the trivial, or striving for perfection].
- Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1.
- The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
- A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 4.3%。
北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- 分期
- 未注明
- 开始
- 2025-09
- 登记号
- NCT07725783
年龄 10 岁 至 60 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- 分期
- I期
- 开始
- 2024-03
- 登记号
- NCT06340204
年龄 8 岁 至 40 岁(登记的条件)
牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、济南
- 正在招募A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- 分期
- I期
- 开始
- 2025-05
- 登记号
- NCT06926283
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文7
- Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.
- Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
- Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
- Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
- Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
- Irinotecan and Temozolomide for Ewing Sarcoma
- Anlotinib and Irinotecan for Ewing Sarcoma
- A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 1.1%。
北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募KPD Consolidation After ASCT in NDMM Patients
- 分期
- II/III期
- 开始
- 2025-03
- 登记号
- NCT06879379
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院;另有 1 家列出的医院为研究中心上海、北京
- 正在招募Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- 分期
- 未注明
- 开始
- 2025-07
- 登记号
- NCT07296627
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Risk Stratification and MRD-driven Maintenance for MM After ASCT
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06697483
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、哈尔滨
- 即将招募ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- 分期
- 未注明
- 开始
- 2025-12
- 登记号
- NCT07320326
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 即将招募A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06369935
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 正在招募A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-02
- 登记号
- NCT07258511
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安
- 正在招募A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- 分期
- I期
- 开始
- 2026-07
- 登记号
- NCT07652281
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT06514508
年龄 18 岁 至 78 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-10
- 登记号
- NCT06049290
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛
- 正在招募A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- 分期
- I/II期
- 开始
- 2021-09
- 登记号
- NCT04973605
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛
- 即将招募A Open-Label Phase in Participants With Multiple Myeloma
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07764861
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文19
- Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.
- Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.
- Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation:
- The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.
- Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.
- The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050.
- Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.
- Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes.
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
- Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.
- Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
- Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
- Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.
- Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
- Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma.
- The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
- Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
- Extramedullary plasmacytoma of the nasal inferior turbinate: a case report.
中文论文(未计入)13
- [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Guidelines for the diagnosis and management of multiple myeloma: 2024 updates].
- [Treatment options for multiple myeloma with renal injury].
- [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
- [Current status and challenges of immunotherapy for multiple myeloma].
- [A single-center retrospective analysis of 100 consecutive cases treated with lenalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma].
- [A message to the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)-a step further, a level higher].
- [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].
- [Analysis of clinical features of multiple myeloma with t(8;14)(q24;q32)].
- [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
- [Progress in the treatment of multiple myeloma with daratumumab].
- [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].
- [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
- ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- KPD Consolidation After ASCT in NDMM Patients
- Risk Stratification and MRD-driven Maintenance for MM After ASCT
- A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
- Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
- Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
- A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
- A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Open-Label Phase in Participants With Multiple Myeloma
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 19 篇,占 8.4%。
北京有 10 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 7
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07441291
年龄 3 岁 至 79 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- 分期
- 不分期
- 开始
- 2024-10
- 登记号
- NCT06581081
年龄 12 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- 分期
- I/II期
- 开始
- 2024-11
- 登记号
- NCT06880913
年龄 12 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
- 即将招募Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- 分期
- 不分期
- 开始
- 2026-11
- 登记号
- NCT07919470
年龄 14 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院;另有 1 家列出的医院为研究中心北京、廊坊
- 正在招募Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- 分期
- II期
- 开始
- 2025-01
- 登记号
- NCT07244406
年龄 3 岁 至 25 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- 分期
- I期
- 开始
- 2024-09
- 登记号
- NCT06927466
年龄 3 岁 至 25 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、南昌、徐州、武汉、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文19
- Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.
- Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
- Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
- CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.
- Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.
- Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
- ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
- CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.
- Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.
- Long-Term Survival and Immune Reconstitution of Donor-Derived Chimeric Antigen Receptor T-Cell Therapy for Childhood Molecular Relapse of B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
- Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
- CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.
- Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.
- Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
- The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.
- Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
- Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
- Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
- Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Safety and Efficacy Evaluation of IM19 CAR-T Cells
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 29 篇,占 7.0%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- 分期
- 未注明
- 开始
- 2026-06
- 登记号
- NCT07586735
年龄 40 岁 至 60 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07629947
年龄 18 岁 至 40 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募A Prediction Model in Pregnant Women With Aplastic Anemia
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07101770
年龄 20 岁 至 50 岁;仅女性(登记的条件)
牵头:北京大学人民医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文29
- Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.
- The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.
- The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.
- Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.
- The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Study From the Chinese
- Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.
- TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia.
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.
- Ovarian tissue cryopreservation after graft failure of allogeneic hematopoietic stem cell transplantation: first report and literature review.
- The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry group.
- BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.
- Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.
- Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation.
- Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem
- Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.
- Repair of dysfunctional bone marrow endothelial cells alleviates aplastic anemia.
- Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia.
- Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.
- Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
- Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation.
- A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity.
- The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia.
- Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.
- The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents.
- Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study.
- Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.
- Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.
- The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia.
- Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings.
中文论文(未计入)5
- [Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].
- [Severe cardiotoxic characteristics associated with allogeneic hematopoietic stem cell transplantation preconditioning in patients with aplastic anemia].
- [Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation].
- [Safety and survival analysis of haplo-identical hematopoietic stem cell transplantation in patients with severe aplastic anemia who had previous failure to antithymoglobulin treatment].
- [Erythrocytosis after hematopoietic stem cell transplantation: report of 3 cases and literature review].
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- A Prediction Model in Pregnant Women With Aplastic Anemia
- The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.8%。
北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- 分期
- 未注明
- 开始
- 2026-10
- 登记号
- NCT07905066
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院北京
- 正在招募A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07208058
年龄 16 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文7
- Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.
- Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.
- Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.
- COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
- A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.
- Hemophagocytic Lymphohistiocytosis Secondary to Juvenile Myelomonocytic Leukemia: A Case Report and Review of the Literature.
- Hemophagocytic syndrome and neurological involvement in a case of intravascular large B-cell lymphoma.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
血液疾病
血友病 A
Haemophilia A北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Longitudinal Cohort of Thrombosis and Hemostasis Diseases
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT06727669
年龄未注明(登记的条件)
牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆
- 正在招募A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07416526
年龄 12 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 4 篇,占 6.2%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Longitudinal Cohort of Thrombosis and Hemostasis Diseases
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT06727669
年龄未注明(登记的条件)
牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆
- 正在招募BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- 分期
- II期
- 开始
- 2024-12
- 登记号
- NCT06794008
年龄 18 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Thrombotic thrombocytopenic purpura following allogeneic hematopoietic stem cell transplantation: a rare but fatal complication.
- Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study.
- Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura.
- Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 3 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
这些数字背后的记录
牵头的论文2
- Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem
- Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07809724
年龄 18 岁 至 74 岁(登记的条件)
牵头:北京大学人民医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.9%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- 分期
- II期
- 开始
- 2024-12
- 登记号
- NCT06794008
年龄 18 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Primary intraosseous Rosai-Dorfman disease: Clinicopathological features and an assessment of a possible relationship with IgG4-related disease.
- Clinical characterization of malignant lymphoma mimicking IgG4-related disease.
- Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.
- Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.
- Immune phenotype changes in IgG4-related disease: CD161 + Treg and Foxp3 + Treg.
- Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.
- IL-7 Promotes the Expansion of Circulating CD28- Cytotoxic T Lymphocytes in Patients With IgG4-Related Disease via the JAK Signaling.
- Characteristics of IgG4-related disease complicated with allergic rhinitis or chronic rhinosinusitis: a large cross-sectional cohort study.
- Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.
- Needle biopsy compared with surgical biopsy: pitfalls of small biopsy in histologial diagnosis of IgG4-related disease.
- Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.
- Disparities between IgG4-related kidney disease and extrarenal IgG4-related disease in a case-control study based on 450 patients.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)5
- POS1249 CIRCULATING GRANZYME K+ CD8+ T CELLS UNDERLYING THE MECHANISMS OF IgG4-RELATED DISEASE
- POS0922 DIFFERENTIAL DIAGNOSIS OF FOCAL IMMUNOGLOBULIN G4-RELATED SIALADENITIS AND BENIGN SALIVARY MASSES: THE VALUE OF CONTRAST-ENHANCED ULTRASOUND
- Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity
- AB0758 CLINICAL PROFILES DIFFER IN IGG4-RELATED DISEASE WITH AND WITHOUT ATOPY: A LARGE CASE-CONTROL STUDY IN CHINA
- POS1384 DIFFERENT CLINICAL CHARACTERISTICS OF IGG4-RRD PATIENTS AND NON-IGG4-RRD PATIENTS: A LARGE CHINESE COHORT STUDY
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
牵头的论文3
- Single-Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion.
- Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab.
- Risk factors of prolonged ventilation after thymectomy in thymoma myasthenia gravis patients.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
牵头的论文1
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文3
- Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study.
- Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.
- Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.0%。
北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- 分期
- II期
- 开始
- 2024-12
- 登记号
- NCT06794008
年龄 18 岁 至 65 岁(登记的条件)
牵头:北京大学人民医院北京
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
- 正在招募AutoInflammatory Disease Alliance Registry (AIDA)
- 分期
- 未注明
- 开始
- 2020-08
- 登记号
- NCT05200715
年龄未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.
- Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.
- Comparison of different onset ages in patients with Behcet's disease.
- Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.
- Refractory Behçet's disease treated with low-dose interleukin-2: A case report.
早期论文(2016–2020 年)5
- [Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].
- Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.
- A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
- [Capsule endoscopy for Behcet's disease-treatment: five cases reports].
- Outcomes of surgery for patients with Behcet's disease causing aortic pseudoaneurysm: a shift from open surgery to endovascular repair.
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.
- Ivarmacitinib for Refractory Behcet's Syndrome
- Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
- Upadacitinib for Refractory Behcet's Syndrome
- Low-dose IL-2 Treatment on Behcet's Disease
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- AutoInflammatory Disease Alliance Registry (AIDA)
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
戈谢病
Gaucher disease2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 5 家医院列在戈谢病下全国有 41 家医院列在戈谢病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 5 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文7
- Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.
- Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.
- The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models.
- Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.
- Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.
- Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.
- Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07387549
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
先天性膈疝
Congenital diaphragmatic hernia2021–2025 年没有牵头先天性膈疝的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
北京大学人民医院
Peking University People's Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药